AI-driven drug discovery firm TandemAI has announced that has formed a new company with peptide therapeutics maker Perpetual Medicines. The company will keep the TandemAI name, this time using Perpetual Medicines’ expanded range of methods and workflows for small molecule and peptide drug discovery.
TandemAI’s cofounder and CEO Jeff He will head up the new company, while Perpetual Medicines’ cofounder and CEO, Kerry Blanchard, will continue head his company as a separate entity underneath it.
Jeff He said: "TandemAI was established with a vision to transform drug discovery by enabling broad access to the most advanced AI and physics based computational tools for integrated drug discovery."
"With Perpetual’s integrated computational-synthesis platform and experienced leadership, we have a major opportunity to advance and accelerate peptide drug discovery with partners."
Lanny Sun, now a board member at TandemAI played a role in founding both companies. He praised Perpetual Medicines validated AI platform for peptide drug discovery.
Sun said: "The merger positions TandemAI to be a leader in these approaches as well as to explore their application to other modalities."
TandemAI said in a press statement: “[Our] next-generation, cloud-enabled, data-centric, browser-based user interface, TandemViz, expedites easy access to high-performance computation and streamlined data consolidation for drug discovery projects.”
It continued: “Perpetual Medicines is a fully integrated computational peptide therapeutics firm aiming to build a next-generation peptide drug discovery engine.”
